Clinical Research Details
Title:
Treatment Therapy Followed by Stem Cell Transplant for Relapsed Follicular Non-Hodgkin’s Lymphoma
Purpose:
The primary objective of this study is to measure progression-free survival at two years after allogeneic hematopoietic stem cell transplantation (HSCT) using pre-transplant conditioning of fludarabine, cyclophosphamide and rituximab (FCR) for patients with relapsed follicular non-Hodgkin’s lymphoma.
Study Number:
201808052009
Number of Patients:
65
Elgibility:
You may be eligible if you are an adult and have been diagnosed with relapsed follicular non-Hodgkin’s lymphoma.
Treatment:
Participants will receive chemotherapy plus rituximab followed by stem cell transplant.
Principal Investigator:
Enrollment Phone:
(708) 327-3304